Sclerosi multipla (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sclerosi multipla" in Italian language version.

refsWebsite

Global rank Italian rank

148nih.gov

4^th place

9^th place

100doi.org

2^nd place

7^th place

74oadoi.org

799^th place

22^nd place

33web.archive.org

1^st place

17archive.org

6^th place

8^th place

4fda.gov

447^th place

644^th place

3archive.is

87^th place

low place

3aism.it

low place

3bmj.com

1,226^th place

928^th place

2la-sclerosimultipla.net

low place

2neurology.org

9,919^th place

low place

2wiley.com

222^nd place

243^rd place

2aifa.gov.it

low place

6,468^th place

2springer.com

274^th place

393^rd place

2medicalcannabis.it

low place

1worldcat.org

5^th place

26^th place

1unibo.it

4,963^rd place

325^th place

1atlasofms.org

low place

1iss.it

low place

1,085^th place

1mstrust.org.uk

low place

1ucl.ac.uk

1,306^th place

3,226^th place

1treccani.it

182^nd place

6^th place

1mult-sclerosis.org

low place

1aerzteblatt.de

3,043^rd place

low place

1msif.org

low place

1jneurosci.org

low place

8,404^th place

1revneurol.com

low place

1informahealthcare.com

low place

1guardian.co.uk

197^th place

106^th place

1who.int

195^th place

342^nd place

1wikiwix.com

194^th place

345^th place

1webmd.com

1,169^th place

2,954^th place

1jamanetwork.com

2,650^th place

2,089^th place

aerzteblatt.de

Rieckmann et al., Rekombinante Beta-Interferone: Immunmodulatorische Therapie der schubförmigen Multiplen Sklerose. Deutsches Ärzteblatt 93, Ausgabe 46 vom 15. November 1996, Seite A-3022 Testo completo

aifa.gov.it

AIFA Determina 30/2018, su aifa.gov.it.
AIFA Determina 561/2018, su aifa.gov.it.

aism.it

Disfagia, su aism.it, Associazione Italiana Sclerosi multipla. URL consultato il 30 settembre 2012.
(EN) AISM - Studio di Buffalo, su aism.it. URL consultato il 21 settembre 2012.
Non esiste correlazione tra CCSVI e SM, su aism.it, 12 ottobre 2012. URL consultato il 2 novembre 2012.

archive.is

Kurtzke JF, Epidemiologic evidence for multiple sclerosis as an infection, in Clin. Microbiol. Rev., vol. 6, n. 4, ottobre 1993, pp. 382–427, PMC 358295, PMID 8269393. URL consultato il 14 settembre 2012 (archiviato dall'url originale il 5 dicembre 2012).
Petro DJ, Ellenberger C, Treatment of Human Spasticity with Tetrahydrocannabinol, in Journal of Clinical Pharmacology 1981; 21: 413-416, PMID 6271839. URL consultato il 14 ottobre 2022 (archiviato dall'url originale l'11 aprile 2013).
Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R, A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols), in Mult Scler 2012; 18(2): 219-28, PMID 21878454. URL consultato il 14 ottobre 2022 (archiviato dall'url originale l'11 aprile 2013).

archive.org

Ascherio A, Munger KL, Environmental risk factors for multiple sclerosis. Part I: the role of infection, in Ann. Neurol., vol. 61, n. 4, aprile 2007, pp. 288–99, DOI:10.1002/ana.21117, PMID 17444504.
Lublin FD, Reingold SC, Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, in Neurology, vol. 46, n. 4, aprile 1996, pp. 907–11, PMID 8780061.
WI. McDonald, Physicians, subsequence and consequence., in J Neurol Neurosurg Psychiatry, vol. 67, n. 3, settembre 1999, pp. 282-9, PMID 10449547.
Compston A, The 150th anniversary of the first depiction of the lesions of multiple sclerosis, in J. Neurol. Neurosurg. Psychiatr., vol. 51, n. 10, ottobre 1988, pp. 1249–52, DOI:10.1136/jnnp.51.10.1249, ISSN 0022-3050 (WC · ACNP), PMC 1032909, PMID 3066846.
DW. Anderson, JH. Ellenberg; CM. Leventhal; SC. Reingold; M. Rodriguez; DH. Silberberg, Revised estimate of the prevalence of multiple sclerosis in the United States., in Ann Neurol, vol. 31, n. 3, marzo 1992, pp. 333-6, DOI:10.1002/ana.410310317, PMID 1637140.
Ascherio A, Munger KL, Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors, in Ann. Neurol., vol. 61, n. 6, giugno 2007, pp. 504–13, DOI:10.1002/ana.21141, PMID 17492755.
Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R, Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada, in Int J Epidemiol., vol. 27, n. 5, 1998, pp. 845–52, DOI:10.1093/ije/27.5.845, PMID 9839742.
Chari DM, Remyelination in multiple sclerosis, in Int. Rev. Neurobiol., International Review of Neurobiology, vol. 79, 2007, pp. 589–620, DOI:10.1016/S0074-7742(07)79026-8, ISBN 978-0-12-373736-6, PMID 17531860.
Page NG, Bolger JP, Sanders MD, Auditory evoked phosphenes in optic nerve disease, in J. Neurol. Neurosurg. Psychiatr., vol. 45, n. 1, gennaio 1982, pp. 7–12, DOI:10.1136/jnnp.45.1.7, PMC 491258, PMID 7062073.
Kurtzke JF, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), in Neurology, vol. 33, n. 11, 1983, pp. 1444–52, PMID 6685237.
McDonald WI, Compston A, Edan G, et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, in Ann. Neurol., vol. 50, n. 1, luglio 2001, pp. 121–7, DOI:10.1002/ana.1032, PMID 11456302.
Polman CH, Reingold SC, Edan G, et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria", in Ann. Neurol., vol. 58, n. 6, dicembre 2005, pp. 840–6, DOI:10.1002/ana.20703, PMID 16283615.
D. Buck, A. Förschler; C. Lapa; T. Schuster; P. Vollmar; T. Korn; S. Nessler; C. Stadelmann; A. Drzezga; AK. Buck; HJ. Wester, 18F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions., in J Nucl Med, vol. 53, n. 8, agosto 2012, pp. 1269-76, DOI:10.2967/jnumed.111.102608, PMID 22738927.
CH. Polman, SC. Reingold; B. Banwell; M. Clanet; JA. Cohen; M. Filippi; K. Fujihara; E. Havrdova; M. Hutchinson; L. Kappos; FD. Lublin, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria., in Ann Neurol, vol. 69, n. 2, febbraio 2011, pp. 292-302, DOI:10.1002/ana.22366, PMID 21387374.
Cath Smith, Leigh Hale; Kärin Olson; Anthony Schneiders, How does exercise influence fatigue in people with multiple sclerosis?, in Disability and Rehabilitation, vol. 31, n. 9, 2009, pp. 685–692, DOI:10.1080/09638280802273473, PMID 18841515.
Susan O'Sullivan, Physical Rehabilitation Fifth Edition, Philadelphia, F.A. Davis Company, 2007, pp. 136–146, ISBN 978-0-8036-1247-1.
LI. Iezzoni, M. Ogg, Hard lessons from a long hospital stay., in Am J Nurs, vol. 112, n. 4, aprile 2012, pp. 39-42, DOI:10.1097/01.NAJ.0000413457.53110.3a, PMID 22456565.

atlasofms.org

Number of people with MS | Atlas of MS, su www.atlasofms.org. URL consultato il 13 settembre 2020.

bmj.com

jnnp.bmj.com

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; on behalf of the MUSEC Research Group, Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial, in J Neurol Neurosurg Psychiatry. 2012 Jul 12., PMID 22791906.
Zamboni P, Galeotti R, Menegatti E, et al., Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis, in J. Neurol. Neurosurg. Psychiatr., vol. 80, n. 4, aprile 2009, pp. 392–9, DOI:10.1136/jnnp.2008.157164, PMC 2647682, PMID 19060024.

bmj.com

Svendsen KB, Jensen TS, Bach FW, Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial, in British Medical Journal 2004; 329: 253, PMID 15258006.

doi.org

dx.doi.org

Compston A, Coles A, Multiple sclerosis, in Lancet, vol. 372, n. 9648, ottobre 2008, pp. 1502–17, DOI:10.1016/S0140-6736(08)61620-7, PMID 18970977.
Compston A, Coles A, Multiple sclerosis, in Lancet, vol. 359, n. 9313, aprile 2002, pp. 1221–31, DOI:10.1016/S0140-6736(02)08220-X, PMID 11955556.
Ascherio A, Munger KL, Environmental risk factors for multiple sclerosis. Part I: the role of infection, in Ann. Neurol., vol. 61, n. 4, aprile 2007, pp. 288–99, DOI:10.1002/ana.21117, PMID 17444504.
Weinshenker BG, Natural history of multiple sclerosis, in Ann. Neurol., vol. 36, Suppl, 1994, pp. S6–11, DOI:10.1002/ana.410360704, PMID 8017890.
Compston A, The 150th anniversary of the first depiction of the lesions of multiple sclerosis, in J. Neurol. Neurosurg. Psychiatr., vol. 51, n. 10, ottobre 1988, pp. 1249–52, DOI:10.1136/jnnp.51.10.1249, ISSN 0022-3050 (WC · ACNP), PMC 1032909, PMID 3066846.
Lassmann H, The pathology of multiple sclerosis and its evolution, in Philos Trans R Soc Lond B Biol Sci., vol. 354, n. 1390, 29 ottobre 1999, pp. 1635–40, DOI:10.1098/rstb.1999.0508, PMC 1692680, PMID 10603616.
Lassmann H, Multiple sclerosis pathology: evolution of pathogenetic concepts, in Brain Pathology, vol. 15, n. 3, luglio 2005, pp. 217–22, DOI:10.1111/j.1750-3639.2005.tb00523.x, PMID 16196388.
T. Holmøy, A Norse contribution to the history of neurological diseases., in Eur Neurol, vol. 55, n. 1, 2006, pp. 57-8, DOI:10.1159/000091431, PMID 16479124.
Medaer R, Does the history of multiple sclerosis go back as far as the 14th century?, in Acta Neurol. Scand., vol. 60, n. 3, settembre 1979, pp. 189–92, DOI:10.1111/j.1600-0447.1979.tb08970.x, PMID 390966.
Pearce JM, Historical descriptions of multiple sclerosis, in Eur. Neurol., vol. 54, n. 1, 2005, pp. 49–53, DOI:10.1159/000087387, PMID 16103678.
DW. Anderson, JH. Ellenberg; CM. Leventhal; SC. Reingold; M. Rodriguez; DH. Silberberg, Revised estimate of the prevalence of multiple sclerosis in the United States., in Ann Neurol, vol. 31, n. 3, marzo 1992, pp. 333-6, DOI:10.1002/ana.410310317, PMID 1637140.
Marrie RA, Environmental risk factors in multiple sclerosis aetiology, in Lancet Neurol, vol. 3, n. 12, dicembre 2004, pp. 709–18, DOI:10.1016/S1474-4422(04)00933-0, PMID 15556803.
Ascherio A, Munger KL, Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors, in Ann. Neurol., vol. 61, n. 6, giugno 2007, pp. 504–13, DOI:10.1002/ana.21141, PMID 17492755.
Miller DH, Leary SM, Primary-progressive multiple sclerosis, in Lancet Neurol, vol. 6, n. 10, ottobre 2007, pp. 903–12, DOI:10.1016/S1474-4422(07)70243-0, PMID 17884680.
Alwan S, Sadovnick AD, Multiple sclerosis and pregnancy: maternal considerations, in Womens Health (Lond Engl), vol. 8, n. 4, luglio 2012, pp. 399–414, DOI:10.2217/whe.12.33, PMID 22757731.
Alonso A, Hernán MA, Temporal trends in the incidence of multiple sclerosis: a systematic review, in Neurology, vol. 71, n. 2, luglio 2008, pp. 129–35, DOI:10.1212/01.wnl.0000316802.35974.34, PMID 18606967.
M Pugliatti, Sotgiu, S, Rosati, G, The worldwide prevalence of multiple sclerosis, in Clinical neurology and neurosurgery, vol. 104, n. 3, 2002 Jul, pp. 182–91, DOI:10.1016/S0303-8467(02)00036-7, PMID 12127652.
Minagar A, Jy W, Jimenez JJ, Alexander JS., Multiple sclerosis as a vascular disease (PDF), in Neurol Res., vol. 28, n. 3, aprile 2006, pp. 230–5, DOI:10.1179/016164106X98080, PMID 16687046 (archiviato dall'url originale il 16 agosto 2011).
Dyment DA, Ebers GC, Sadovnick AD, Genetics of multiple sclerosis, in Lancet Neurol, vol. 3, n. 92, febbraio 2004, pp. 104–10, DOI:10.1016/S1474-4422(03)00663-X, PMID 14747002.
Ascherio A, Munger KL, Simon KC, Vitamin D and multiple sclerosis, in Lancet Neurol, vol. 9, n. 6, giugno 2010, pp. 599–612, DOI:10.1016/S1474-4422(10)70086-7, PMID 20494325.
Kulie T, Groff A, Redmer J, Hounshell J, Schrager S, Vitamin D: an evidence-based review, in J Am Board Fam Med, vol. 22, n. 6, 2009, pp. 698–706, DOI:10.3122/jabfm.2009.06.090037, PMID 19897699.
Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R, Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada, in Int J Epidemiol., vol. 27, n. 5, 1998, pp. 845–52, DOI:10.1093/ije/27.5.845, PMID 9839742.
Spitsin S, Koprowski H, Role of uric acid in multiple sclerosis, in Curr. Top. Microbiol. Immunol., Current Topics in Microbiology and Immunology, vol. 318, 2008, pp. 325–42, DOI:10.1007/978-3-540-73677-6_13, ISBN 978-3-540-73676-9, PMID 18219824.
Mechelli R. et al., Epstein-Barr virus genetic variants are associated with multiple sclerosis., in Neurology, vol. 84, n. 13, marzo 2015, pp. 1362–8, DOI:10.1212/WNL.0000000000001420, PMC 4388746, PMID 25740864.
Gilden DH, Infectious causes of multiple sclerosis, in The Lancet Neurology, vol. 4, n. 3, marzo 2005, pp. 195–202, DOI:10.1016/S1474-4422(05)01017-3, PMID 15721830.
Chari DM, Remyelination in multiple sclerosis, in Int. Rev. Neurobiol., International Review of Neurobiology, vol. 79, 2007, pp. 589–620, DOI:10.1016/S0074-7742(07)79026-8, ISBN 978-0-12-373736-6, PMID 17531860.
Pittock SJ, Lucchinetti CF, The pathology of MS: new insights and potential clinical applications, in Neurologist, vol. 13, n. 2, marzo 2007, pp. 45–56, DOI:10.1097/01.nrl.0000253065.31662.37, PMID 17351524.
ET. Wood, I. Ronen; A. Techawiboonwong; CK. Jones; PB. Barker; P. Calabresi; D. Harrison; DS. Reich, Investigating axonal damage in multiple sclerosis by diffusion tensor spectroscopy., in J Neurosci, vol. 32, n. 19, maggio 2012, pp. 6665-9, DOI:10.1523/JNEUROSCI.0044-12.2012, PMID 22573688.
Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C, T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis, in Glia, vol. 36, n. 2, novembre 2001, pp. 220–34, DOI:10.1002/glia.1111, PMID 11596130.
A. Petzold, Fraser, C.L., Abegg, M., et al., Diagnosis and classification of optic neuritis, in The Lancet Neurology, vol. 21, n. 12, dec 2022, pp. 1120–1134, DOI:10.1016/S1474-4422(22)00200-9, PMID 36179757.
Page NG, Bolger JP, Sanders MD, Auditory evoked phosphenes in optic nerve disease, in J. Neurol. Neurosurg. Psychiatr., vol. 45, n. 1, gennaio 1982, pp. 7–12, DOI:10.1136/jnnp.45.1.7, PMC 491258, PMID 7062073.
H. Nakajima, T. Hosokawa; M. Sugino; F. Kimura; J. Sugasawa; T. Hanafusa; T. Takahashi, Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis., in BMC Neurol, vol. 10, 2010, p. 45, DOI:10.1186/1471-2377-10-45, PMID 20565857.
Tataru N, Vidal C, Decavel P, Berger E, Rumbach L, Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis, in Neuroepidemiology, vol. 27, n. 1, 2006, pp. 28–32, DOI:10.1159/000094233, PMID 16804331.
Heesen C, Mohr DC, Huitinga I, et al., Stress regulation in multiple sclerosis: current issues and concepts, in Mult. Scler., vol. 13, n. 2, marzo 2007, pp. 143–8, DOI:10.1177/1352458506070772, PMID 17439878.
Martinelli V, Trauma, stress and multiple sclerosis, in Neurol. Sci., vol. 21, 4 Suppl 2, 2000, pp. S849–52, DOI:10.1007/s100720070024, PMID 11205361. URL consultato il 20 settembre 2012 (archiviato dall'url originale il 1º novembre 2013).
J. Correale, MC. Ysrraelit; MP. Fiol, Benign Multiple Sclerosis: Does it exist?, in Curr Neurol Neurosci Rep, vol. 12, n. 5, ottobre 2012, pp. 601-9, DOI:10.1007/s11910-012-0292-5, PMID 22777531.
K. Hawker, Primary progressive multiple sclerosis., in Continuum (Minneap Minn), vol. 16, 5 Multiple Sclerosis, ottobre 2010, pp. 211-25, DOI:10.1212/01.CON.0000389943.81981.3b, PMID 22810607.
(EN) Fred D. Lublin e Stephen C. Reingold, Defining the clinical course of multiple sclerosis: Results of an international survey, in Neurology, vol. 46, n. 4, aprile 1996, pp. 907–911, DOI:10.1212/WNL.46.4.907, PMID 8780061.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH, Defining the clinical course of multiple sclerosis: the 2013 revisions, in Neurology, vol. 83, n. 3, 2014, pp. 278–86, DOI:10.1212/WNL.0000000000000560, PMC 4117366, PMID 24871874.
Trojano M, Paolicelli D, The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes, in Neurol. Sci., vol. 22, Suppl 2, novembre 2001, pp. S98–102, DOI:10.1007/s100720100044, PMID 11794488. URL consultato il 17 ottobre 2011 (archiviato dall'url originale il 20 ottobre 2014).
Poser CM, Brinar VV, Diagnostic criteria for multiple sclerosis: an historical review, in Clin Neurol Neurosurg, vol. 106, n. 3, giugno 2004, pp. 147–58, DOI:10.1016/j.clineuro.2004.02.004, PMID 15177763.
McDonald WI, Compston A, Edan G, et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, in Ann. Neurol., vol. 50, n. 1, luglio 2001, pp. 121–7, DOI:10.1002/ana.1032, PMID 11456302.
Polman CH, Reingold SC, Edan G, et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria", in Ann. Neurol., vol. 58, n. 6, dicembre 2005, pp. 840–6, DOI:10.1002/ana.20703, PMID 16283615.
Rashid W, Miller DH, Recent advances in neuroimaging of multiple sclerosis, in Semin Neurol, vol. 28, n. 1, febbraio 2008, pp. 46–55, DOI:10.1055/s-2007-1019127, PMID 18256986.
G. Poloni, A. Minagar; EM. Haacke; R. Zivadinov, Recent developments in imaging of multiple sclerosis., in Neurologist, vol. 17, n. 4, luglio 2011, pp. 185-204, DOI:10.1097/NRL.0b013e31821a2643, PMID 21712664.
D. Buck, A. Förschler; C. Lapa; T. Schuster; P. Vollmar; T. Korn; S. Nessler; C. Stadelmann; A. Drzezga; AK. Buck; HJ. Wester, 18F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions., in J Nucl Med, vol. 53, n. 8, agosto 2012, pp. 1269-76, DOI:10.2967/jnumed.111.102608, PMID 22738927.
Link H, Huang YM, Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness, in J. Neuroimmunol., vol. 180, 1–2, novembre 2006, pp. 17–28, DOI:10.1016/j.jneuroim.2006.07.006, PMID 16945427.
CH. Polman, SC. Reingold; B. Banwell; M. Clanet; JA. Cohen; M. Filippi; K. Fujihara; E. Havrdova; M. Hutchinson; L. Kappos; FD. Lublin, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria., in Ann Neurol, vol. 69, n. 2, febbraio 2011, pp. 292-302, DOI:10.1002/ana.22366, PMID 21387374.
AJ. Thompson, BL. Banwell; F. Barkhof; WM. Carroll; T. Coetzee; G. Comi; J. Correale; F. Fazekas; M. Filippi; MS. Freedman; K. Fujihara, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria., in Lancet Neurol, vol. 17, n. 2, febbraio 2018, pp. 162-173, DOI:10.1016/S1474-4422(17)30470-2, PMID 29275977.
LA. Rolak, JO. Fleming, The differential diagnosis of multiple sclerosis., in Neurologist, vol. 13, n. 2, marzo 2007, pp. 57-72, DOI:10.1097/01.nrl.0000254705.39956.34, PMID 17351525.
Solomon AJ et al., The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study (PDF), in Neurology, vol. 87, n. 13, settembre 2016, pp. 1393-9, DOI:10.1212/WNL.0000000000003152, PMID 27581217.
Burton JM, O'Connor PW, Hohol M, Beyene J, Oral versus intravenous steroids for treatment of relapses in multiple sclerosis, in Jodie M Burton (a cura di), Cochrane Database Syst Rev, n. 3, 2009, pp. CD006921, DOI:10.1002/14651858.CD006921.pub2, PMID 19588409.
G. Filippini, L. Munari; B. Incorvaia; GC. Ebers; C. Polman; R. D'Amico; GP. Rice, Interferons in relapsing remitting multiple sclerosis: a systematic review., in Lancet, vol. 361, n. 9357, febbraio 2003, pp. 545-52, DOI:10.1016/S0140-6736(03)12512-3, PMID 12598138.
L. Munari, R. Lovati; A. Boiko, Therapy with glatiramer acetate for multiple sclerosis., in Cochrane Database Syst Rev, n. 1, 2004, pp. CD004678, DOI:10.1002/14651858.CD004678, PMID 14974077.
CH. Polman, PW. O'Connor; E. Havrdova; M. Hutchinson; L. Kappos; DH. Miller; JT. Phillips; FD. Lublin; G. Giovannoni; A. Wajgt; M. Toal, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis., in N Engl J Med, vol. 354, n. 9, marzo 2006, pp. 899-910, DOI:10.1056/NEJMoa044397, PMID 16510744.
JA. Cohen, F. Barkhof; G. Comi; HP. Hartung; BO. Khatri; X. Montalban; J. Pelletier; R. Capra; P. Gallo; G. Izquierdo; K. Tiel-Wilck, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis., in N Engl J Med, vol. 362, n. 5, febbraio 2010, pp. 402-15, DOI:10.1056/NEJMoa0907839, PMID 20089954.
L. Kappos, EW. Radue; P. O'Connor; C. Polman; R. Hohlfeld; P. Calabresi; K. Selmaj; C. Agoropoulou; M. Leyk; L. Zhang-Auberson; P. Burtin, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis., in N Engl J Med, vol. 362, n. 5, febbraio 2010, pp. 387-401, DOI:10.1056/NEJMoa0909494, PMID 20089952.
F. Martinelli Boneschi, M. Rovaris; R. Capra; G. Comi, Mitoxantrone for multiple sclerosis., in Cochrane Database Syst Rev, n. 4, 2005, pp. CD002127, DOI:10.1002/14651858.CD002127.pub2, PMID 16235298.
Magne D, Mézin F, Palmer G, Guerne PA, The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha, in Inflamm. Res., vol. 55, n. 11, 2006, pp. 469–75, DOI:10.1007/s00011-006-5196-x, PMID 17122964.
Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study, in Lancet Neurol, vol. 13, n. 7, 2014, pp. 657–65, DOI:10.1016/S1474-4422(14)70068-7, PMID 24794721.
Kita M, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Sarda SP, Agarwal S, Kong J, Zhang A, Viglietta V, Sheikh SI, Seidman E, Dawson KT, Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study, in Mult. Scler., vol. 20, n. 2, 2014, pp. 253–7, DOI:10.1177/1352458513507818, PMID 24150778.
Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S, Zhang A, Sheikh SI, Seidman E, Dawson KT, Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study, in Mult. Scler., vol. 20, n. 2, 2014, pp. 243–52, DOI:10.1177/1352458513507817, PMID 24150779.
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA, Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes, in Lancet Neurol, vol. 10, n. 4, 2011, pp. 338–48, DOI:10.1016/S1474-4422(11)70020-5, PMID 21397567.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial, in Lancet, vol. 380, n. 9856, 2012, pp. 1829–39, DOI:10.1016/S0140-6736(12)61768-1, PMID 23122650.
Comi G, Treatment of multiple sclerosis: role of natalizumab, in Neurol. Sci., 30, Suppl 2, S2, ottobre 2009, pp. S155–8, DOI:10.1007/s10072-009-0147-2, PMID 19882365.
Johnson KP, Control of multiple sclerosis relapses with immunomodulating agents, in J. Neurol. Sci., vol. 256, Suppl 1, 2007, pp. S23–8, DOI:10.1016/j.jns.2007.01.060, PMID 17350652.
Martinelli Boneschi F, Rovaris M, Capra R, Comi G, Mitoxantrone for multiple sclerosis, in Filippo Martinelli Boneschi (a cura di), Cochrane database of systematic reviews (Online), n. 4, 2005, pp. CD002127, DOI:10.1002/14651858.CD002127.pub2, PMID 16235298.
Leary SM, Thompson AJ, Primary progressive multiple sclerosis: current and future treatment options, in CNS Drugs, vol. 19, n. 5, 2005, pp. 369–76, DOI:10.2165/00023210-200519050-00001, PMID 15907149.
Munari L, Lovati R, Boiko A, Therapy with glatiramer acetate for multiple sclerosis, in Luca M. Munari (a cura di), Cochrane database of systematic reviews (Online), n. 1, 2004, pp. CD004678, DOI:10.1002/14651858.CD004678, PMID 14974077.
Tremlett H, Oger J, Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis, in J. Neurol., vol. 251, n. 11, novembre 2004, pp. 1297–303, DOI:10.1007/s00415-004-0619-5, PMID 15592724.
Kesselring J, Beer S, Symptomatic therapy and neurorehabilitation in multiple sclerosis, in The Lancet Neurology, vol. 4, n. 10, 2005, pp. 643–52, DOI:10.1016/S1474-4422(05)70193-9, PMID 16168933.
A. Kheder, KP. Nair, Spasticity: pathophysiology, evaluation and management., in Pract Neurol, vol. 12, n. 5, ottobre 2012, pp. 289-98, DOI:10.1136/practneurol-2011-000155, PMID 22976059.
Cath Smith, Leigh Hale; Kärin Olson; Anthony Schneiders, How does exercise influence fatigue in people with multiple sclerosis?, in Disability and Rehabilitation, vol. 31, n. 9, 2009, pp. 685–692, DOI:10.1080/09638280802273473, PMID 18841515.
Stroud NM, Minahan CL, The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosis, in Health and Quality of Life Outcomes, vol. 7, 2009, p. 68, DOI:10.1186/1477-7525-7-68, PMC 2717927, PMID 19619337.
Rietberg MB, Brooks D, Uitdehaag BMJ, Kwakkel G, Exercise therapy for multiple sclerosis, in Gert Kwakkel (a cura di), Cochrane Database of Systematic Reviews, CD003980, n. 1, 2005, pp. CD003980, DOI:10.1002/14651858.CD003980.pub2, PMID 15674920.
Dalgas U, Stenager E, Jakobsen J et al., Resistance training improves muscle strength and functional capacity in multiple sclerosis, in Neurology, vol. 73, n. 18, 2009, pp. 1478–1484, DOI:10.1212/WNL.0b013e3181bf98b4, PMID 19884575.
SL Davis, Wilson, TE, White, AT, Frohman, EM, Thermoregulation in multiple sclerosis., in Journal of applied physiology (Bethesda, Md. : 1985), vol. 109, n. 5, 2010 Nov, pp. 1531–7, DOI:10.1152/japplphysiol.00460.2010, PMC 2980380, PMID 20671034.
Kubajewska I, Constantinescu CS, Cannabinoids and experimental models of multiple sclerosis, in Immunobiology 2010; 215(8): 647-57, DOI:10.1016/j.imbio.2009.08.004, PMID 19765854.
de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J, Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects, in Neuropharmacology 2012; 62(7): 2299-308, DOI:10.1016/j.neuropharm.2012.01.030, PMID 22342378.
Buccellato E, Carretta D, Utan A, Cavina C, Speroni E, Grassi G, Candeletti S, Romualdi P, Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis, in J Ethnopharmacol 2011; 133(3): 1033-1038, DOI:10.1016/j.jep.2010.11.035, PMID 21094240.
BA. Cree, 2014 multiple sclerosis therapeutic update., in Neurohospitalist, vol. 4, n. 2, aprile 2014, pp. 63-5, DOI:10.1177/1941874414525410, PMID 24707333.
Olsen SA, A review of complementary and alternative medicine (CAM) by people with multiple sclerosis, in Occup Ther Int, vol. 16, n. 1, 2009, pp. 57–70, DOI:10.1002/oti.266, PMID 19222053.
Farinotti M, Simi S, Di Pietrantonj C, et al., Dietary interventions for multiple sclerosis, in Mariangela Farinotti (a cura di), Cochrane database of systematic reviews (Online), n. 1, 2007, pp. CD004192, DOI:10.1002/14651858.CD004192.pub2, PMID 17253500.
Bennett M, Heard R, Hyperbaric oxygen therapy for multiple sclerosis, in Michael H Bennett (a cura di), Cochrane database of systematic reviews (Online), n. 1, 2004, pp. CD003057, DOI:10.1002/14651858.CD003057.pub2, PMID 14974004.
Phadke JG, Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland, in J. Neurol. Neurosurg. Psychiatr., vol. 50, n. 5, maggio 1987, pp. 523–31, DOI:10.1136/jnnp.50.5.523, PMC 1031962, PMID 3495637.
LI. Iezzoni, M. Ogg, Hard lessons from a long hospital stay., in Am J Nurs, vol. 112, n. 4, aprile 2012, pp. 39-42, DOI:10.1097/01.NAJ.0000413457.53110.3a, PMID 22456565.
Cohen JA, Emerging therapies for relapsing multiple sclerosis, in Arch. Neurol., vol. 66, n. 7, luglio 2009, pp. 821–8, DOI:10.1001/archneurol.2009.104, PMID 19597083.
Kappos L, EW Radue, P O'Connor, C Polman, R Hohlfeld, P Calabresi, K Selmaj, C Agoropoulou e M Leyk, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, in N Eng J Med, vol. 362, n. 5, febbraio 2010, pp. 387–401, DOI:10.1056/NEJMoa0909494, PMID 20089952.
Cohen JA, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, J Pelletier, R Capra e P Gallo, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, in N Eng J Med, vol. 362, n. 5, febbraio 2010, pp. 402–415, DOI:10.1056/NEJMoa0907839, PMID 20089954.
M. Gironi, F. Martinelli-Boneschi; P. Sacerdote; C. Solaro; M. Zaffaroni; R. Cavarretta; L. Moiola; S. Bucello; M. Radaelli; V. Pilato; M. Rodegher, A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis., in Mult Scler, vol. 14, n. 8, settembre 2008, pp. 1076-83, DOI:10.1177/1352458508095828, PMID 18728058.
Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G, A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis, in Multiple Sclerosis, vol. 14, n. 8, 2008, pp. 1076–83, DOI:10.1177/1352458508095828, PMID 18728058.
YP. Agrawal, Low dose naltrexone therapy in multiple sclerosis., in Med Hypotheses, vol. 64, n. 4, 2005, pp. 721-4, DOI:10.1016/j.mehy.2004.09.024, PMID 15694688.
Harris VK, Sadiq SA, Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making, in Mol Diagn Ther, vol. 13, n. 4, 2009, pp. 225–44, DOI:10.2165/11313470-000000000-00000, PMID 19712003.
Zamboni P, Galeotti R, Menegatti E, et al., Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis, in J. Neurol. Neurosurg. Psychiatr., vol. 80, n. 4, aprile 2009, pp. 392–9, DOI:10.1136/jnnp.2008.157164, PMC 2647682, PMID 19060024.
Qiu J, Venous abnormalities and multiple sclerosis: another breakthrough claim?, in Lancet Neurol, vol. 9, n. 5, maggio 2010, pp. 464–5, DOI:10.1016/S1474-4422(10)70098-3, PMID 20398855.
Ghezzi A, Comi G, Federico A, Chronic cerebro-spinal venous insufficiency (CCSVI) and multiple sclerosis, in Neurol. Sci., vol. 32, n. 1, febbraio 2011, pp. 17–21, DOI:10.1007/s10072-010-0458-3, PMID 21161309.
Dorne H, Zaidat OO, Fiorella D, Hirsch J, Prestigiacomo C, Albuquerque F, Tarr RW., Chronic cerebrospinal venous insufficiency and the doubtful promise of an endovascular treatment for multiple sclerosis, in J NeuroIntervent Surg, vol. 2, n. 4, ottobre 2010, pp. 309–311, DOI:10.1136/jnis.2010.003947, PMID 21990639.
Khan O, Filippi M, Freedman MS, Barkhof F, Dore-Duffy P, Lassmann H, Trapp B, Bar-Or A, Zak I, Siegel MJ, Lisak R, Chronic cerebrospinal venous insufficiency and multiple sclerosis, in Annals of neurology, vol. 67, n. 3, Annals of Neurology, 12 febbraio 2010, pp. 286–90, DOI:10.1002/ana.22001, PMID 20373339.
(EN) Claudio Baracchini et al., No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset, in Annals of Neurology, vol. 69, n. 1, DOI:10.1002/ana.22228.
(EN) Paolo Zamboni, Luigi Tesio e Stefania Galimberti, Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis, in JAMA Neurology, vol. 75, n. 1, 1º gennaio 2018, DOI:10.1001/jamaneurol.2017.3825. URL consultato l'8 marzo 2018.

fda.gov

(EN) FDA approves new multiple sclerosis treatment Aubagio, su fda.gov, FDA. URL consultato il 1º ottobre 2012.
(EN) FDA approves first oral drug to reduce MS relapses, su fda.gov. URL consultato il 1º ottobre 2012.
FDA approves new multiple sclerosis treatment Aubagio, su fda.gov, US FDA. URL consultato il 14 settembre 2012.
FDA press release on approval of Gilenya, su fda.gov.

guardian.co.uk

Tim Adams, Gut instinct: the miracle of the parasitic hookworm, in The Observer, 23 maggio 2010.

informahealthcare.com

Truini A, Galeotti F, Cruccu G., Treating pain in multiple sclerosis ^{[collegamento interrotto]}, in Expert Opin Pharmacother 2011; 12(15): 2355-68., PMID 21916786.

iss.it

epicentro.iss.it

Aspetti epidemiologici della sclerosi multipla, su epicentro.iss.it, EpiCentro - Istituto Superiore di Sanità. URL consultato il 12 settembre 2014.

jamanetwork.com

(EN) Paolo Zamboni, Luigi Tesio e Stefania Galimberti, Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis, in JAMA Neurology, vol. 75, n. 1, 1º gennaio 2018, DOI:10.1001/jamaneurol.2017.3825. URL consultato l'8 marzo 2018.

jneurosci.org

Arevalo-Martin A et al, Therapeutic action of cannabinoids in a murine model of multiple sclerosis, in J Neurosci 2003; 23(7): 2511-2516.

la-sclerosimultipla.net

I sintomi, su la-sclerosimultipla.net. URL consultato il 1º ottobre 2012.
Sclerosimultipla.net - Decorso, su la-sclerosimultipla.net. URL consultato il 28 settembre 2012.

medicalcannabis.it

Martyn CN et al, Nabilone in the treatment of multiple sclerosis, in Lancet 1995;345:579, PMID 7776785.
John Zajicek et al. on behalf of the UK MS Research Group, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial (PDF), in Lancet 2003 8; 362(9395): 1517-1526, PMID 14615106.

msif.org

(EN) Antioxidants ^{[collegamento interrotto]}, su msif.org, Multiple sclerosis - International federation. URL consultato il 21 settembre 2012.

mstrust.org.uk

Who gets MS?, su mstrust.org.uk, Multiple Sclerosis Trust, 30 dicembre 2009. URL consultato il 18 aprile 2011.

mult-sclerosis.org

(EN) Secondary Progressive Multiple Sclerosis, su mult-sclerosis.org. URL consultato il 25 settembre 2012.

neurology.org

Gronseth GS, Ashman EJ, Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Neurology, vol. 54, n. 9, maggio 2000, pp. 1720–5, PMID 10802774.
Rog DJ, Nurmikko TJ, Friede T, Young CA, Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis, in Neurology 2005; 65(6): 812-9, PMID 16186518.

nih.gov

ncbi.nlm.nih.gov

Compston A, Coles A, Multiple sclerosis, in Lancet, vol. 372, n. 9648, ottobre 2008, pp. 1502–17, DOI:10.1016/S0140-6736(08)61620-7, PMID 18970977.
Rosati G, The prevalence of multiple sclerosis in the world: an update, in Neurol. Sci., vol. 22, n. 2, aprile 2001, pp. 117–39, PMID 11603614.
Clanet M, Jean-Martin Charcot. 1825 to 1893 (PDF), in Int MS J, vol. 15, n. 2, giugno 2008, pp. 59–61, PMID 18782501. URL consultato il 14 settembre 2012 (archiviato dall'url originale il 30 marzo 2019).
* Charcot, J., Histologie de la sclerose en plaques, in Gazette des hopitaux, Paris, vol. 41, 1868, pp. 554–5.
Compston A, Coles A, Multiple sclerosis, in Lancet, vol. 359, n. 9313, aprile 2002, pp. 1221–31, DOI:10.1016/S0140-6736(02)08220-X, PMID 11955556.
Ascherio A, Munger KL, Environmental risk factors for multiple sclerosis. Part I: the role of infection, in Ann. Neurol., vol. 61, n. 4, aprile 2007, pp. 288–99, DOI:10.1002/ana.21117, PMID 17444504.
Lublin FD, Reingold SC, Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, in Neurology, vol. 46, n. 4, aprile 1996, pp. 907–11, PMID 8780061.
Weinshenker BG, Natural history of multiple sclerosis, in Ann. Neurol., vol. 36, Suppl, 1994, pp. S6–11, DOI:10.1002/ana.410360704, PMID 8017890.
WI. McDonald, Physicians, subsequence and consequence., in J Neurol Neurosurg Psychiatry, vol. 67, n. 3, settembre 1999, pp. 282-9, PMID 10449547.
Compston A, The 150th anniversary of the first depiction of the lesions of multiple sclerosis, in J. Neurol. Neurosurg. Psychiatr., vol. 51, n. 10, ottobre 1988, pp. 1249–52, DOI:10.1136/jnnp.51.10.1249, ISSN 0022-3050 (WC · ACNP), PMC 1032909, PMID 3066846.
Lassmann H, The pathology of multiple sclerosis and its evolution, in Philos Trans R Soc Lond B Biol Sci., vol. 354, n. 1390, 29 ottobre 1999, pp. 1635–40, DOI:10.1098/rstb.1999.0508, PMC 1692680, PMID 10603616.
Lassmann H, Multiple sclerosis pathology: evolution of pathogenetic concepts, in Brain Pathology, vol. 15, n. 3, luglio 2005, pp. 217–22, DOI:10.1111/j.1750-3639.2005.tb00523.x, PMID 16196388.
T. Holmøy, A Norse contribution to the history of neurological diseases., in Eur Neurol, vol. 55, n. 1, 2006, pp. 57-8, DOI:10.1159/000091431, PMID 16479124.
Medaer R, Does the history of multiple sclerosis go back as far as the 14th century?, in Acta Neurol. Scand., vol. 60, n. 3, settembre 1979, pp. 189–92, DOI:10.1111/j.1600-0447.1979.tb08970.x, PMID 390966.
Pearce JM, Historical descriptions of multiple sclerosis, in Eur. Neurol., vol. 54, n. 1, 2005, pp. 49–53, DOI:10.1159/000087387, PMID 16103678.
DW. Anderson, JH. Ellenberg; CM. Leventhal; SC. Reingold; M. Rodriguez; DH. Silberberg, Revised estimate of the prevalence of multiple sclerosis in the United States., in Ann Neurol, vol. 31, n. 3, marzo 1992, pp. 333-6, DOI:10.1002/ana.410310317, PMID 1637140.
Kurtzke JF, Epidemiologic evidence for multiple sclerosis as an infection, in Clin. Microbiol. Rev., vol. 6, n. 4, ottobre 1993, pp. 382–427, PMC 358295, PMID 8269393. URL consultato il 14 settembre 2012 (archiviato dall'url originale il 5 dicembre 2012).
Marrie RA, Environmental risk factors in multiple sclerosis aetiology, in Lancet Neurol, vol. 3, n. 12, dicembre 2004, pp. 709–18, DOI:10.1016/S1474-4422(04)00933-0, PMID 15556803.
Ascherio A, Munger KL, Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors, in Ann. Neurol., vol. 61, n. 6, giugno 2007, pp. 504–13, DOI:10.1002/ana.21141, PMID 17492755.
Miller DH, Leary SM, Primary-progressive multiple sclerosis, in Lancet Neurol, vol. 6, n. 10, ottobre 2007, pp. 903–12, DOI:10.1016/S1474-4422(07)70243-0, PMID 17884680.
Alwan S, Sadovnick AD, Multiple sclerosis and pregnancy: maternal considerations, in Womens Health (Lond Engl), vol. 8, n. 4, luglio 2012, pp. 399–414, DOI:10.2217/whe.12.33, PMID 22757731.
Alonso A, Hernán MA, Temporal trends in the incidence of multiple sclerosis: a systematic review, in Neurology, vol. 71, n. 2, luglio 2008, pp. 129–35, DOI:10.1212/01.wnl.0000316802.35974.34, PMID 18606967.
M Pugliatti, Sotgiu, S, Rosati, G, The worldwide prevalence of multiple sclerosis, in Clinical neurology and neurosurgery, vol. 104, n. 3, 2002 Jul, pp. 182–91, DOI:10.1016/S0303-8467(02)00036-7, PMID 12127652.
Minagar A, Jy W, Jimenez JJ, Alexander JS., Multiple sclerosis as a vascular disease (PDF), in Neurol Res., vol. 28, n. 3, aprile 2006, pp. 230–5, DOI:10.1179/016164106X98080, PMID 16687046 (archiviato dall'url originale il 16 agosto 2011).
Dyment DA, Ebers GC, Sadovnick AD, Genetics of multiple sclerosis, in Lancet Neurol, vol. 3, n. 92, febbraio 2004, pp. 104–10, DOI:10.1016/S1474-4422(03)00663-X, PMID 14747002.
Ascherio A, Munger KL, Simon KC, Vitamin D and multiple sclerosis, in Lancet Neurol, vol. 9, n. 6, giugno 2010, pp. 599–612, DOI:10.1016/S1474-4422(10)70086-7, PMID 20494325.
Kulie T, Groff A, Redmer J, Hounshell J, Schrager S, Vitamin D: an evidence-based review, in J Am Board Fam Med, vol. 22, n. 6, 2009, pp. 698–706, DOI:10.3122/jabfm.2009.06.090037, PMID 19897699.
Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R, Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada, in Int J Epidemiol., vol. 27, n. 5, 1998, pp. 845–52, DOI:10.1093/ije/27.5.845, PMID 9839742.
Spitsin S, Koprowski H, Role of uric acid in multiple sclerosis, in Curr. Top. Microbiol. Immunol., Current Topics in Microbiology and Immunology, vol. 318, 2008, pp. 325–42, DOI:10.1007/978-3-540-73677-6_13, ISBN 978-3-540-73676-9, PMID 18219824.
Mechelli R. et al., Epstein-Barr virus genetic variants are associated with multiple sclerosis., in Neurology, vol. 84, n. 13, marzo 2015, pp. 1362–8, DOI:10.1212/WNL.0000000000001420, PMC 4388746, PMID 25740864.
Gilden DH, Infectious causes of multiple sclerosis, in The Lancet Neurology, vol. 4, n. 3, marzo 2005, pp. 195–202, DOI:10.1016/S1474-4422(05)01017-3, PMID 15721830.
Chari DM, Remyelination in multiple sclerosis, in Int. Rev. Neurobiol., International Review of Neurobiology, vol. 79, 2007, pp. 589–620, DOI:10.1016/S0074-7742(07)79026-8, ISBN 978-0-12-373736-6, PMID 17531860.
Pittock SJ, Lucchinetti CF, The pathology of MS: new insights and potential clinical applications, in Neurologist, vol. 13, n. 2, marzo 2007, pp. 45–56, DOI:10.1097/01.nrl.0000253065.31662.37, PMID 17351524.
MJ. Sá, Physiopathology of symptoms and signs in multiple sclerosis., in Arq Neuropsiquiatr, vol. 70, n. 9, settembre 2012, pp. 733-40, PMID 22990733.
ET. Wood, I. Ronen; A. Techawiboonwong; CK. Jones; PB. Barker; P. Calabresi; D. Harrison; DS. Reich, Investigating axonal damage in multiple sclerosis by diffusion tensor spectroscopy., in J Neurosci, vol. 32, n. 19, maggio 2012, pp. 6665-9, DOI:10.1523/JNEUROSCI.0044-12.2012, PMID 22573688.
Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C, T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis, in Glia, vol. 36, n. 2, novembre 2001, pp. 220–34, DOI:10.1002/glia.1111, PMID 11596130.
A. Petzold, Fraser, C.L., Abegg, M., et al., Diagnosis and classification of optic neuritis, in The Lancet Neurology, vol. 21, n. 12, dec 2022, pp. 1120–1134, DOI:10.1016/S1474-4422(22)00200-9, PMID 36179757.
Page NG, Bolger JP, Sanders MD, Auditory evoked phosphenes in optic nerve disease, in J. Neurol. Neurosurg. Psychiatr., vol. 45, n. 1, gennaio 1982, pp. 7–12, DOI:10.1136/jnnp.45.1.7, PMC 491258, PMID 7062073.
H. Nakajima, T. Hosokawa; M. Sugino; F. Kimura; J. Sugasawa; T. Hanafusa; T. Takahashi, Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis., in BMC Neurol, vol. 10, 2010, p. 45, DOI:10.1186/1471-2377-10-45, PMID 20565857.
Kurtzke JF, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), in Neurology, vol. 33, n. 11, 1983, pp. 1444–52, PMID 6685237.
Tataru N, Vidal C, Decavel P, Berger E, Rumbach L, Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis, in Neuroepidemiology, vol. 27, n. 1, 2006, pp. 28–32, DOI:10.1159/000094233, PMID 16804331.
Heesen C, Mohr DC, Huitinga I, et al., Stress regulation in multiple sclerosis: current issues and concepts, in Mult. Scler., vol. 13, n. 2, marzo 2007, pp. 143–8, DOI:10.1177/1352458506070772, PMID 17439878.
Martinelli V, Trauma, stress and multiple sclerosis, in Neurol. Sci., vol. 21, 4 Suppl 2, 2000, pp. S849–52, DOI:10.1007/s100720070024, PMID 11205361. URL consultato il 20 settembre 2012 (archiviato dall'url originale il 1º novembre 2013).
J. Correale, MC. Ysrraelit; MP. Fiol, Benign Multiple Sclerosis: Does it exist?, in Curr Neurol Neurosci Rep, vol. 12, n. 5, ottobre 2012, pp. 601-9, DOI:10.1007/s11910-012-0292-5, PMID 22777531.
K. Hawker, Primary progressive multiple sclerosis., in Continuum (Minneap Minn), vol. 16, 5 Multiple Sclerosis, ottobre 2010, pp. 211-25, DOI:10.1212/01.CON.0000389943.81981.3b, PMID 22810607.
Fontaine B, Borderline forms of multiple sclerosis, in Rev. Neurol. (Paris), vol. 157, 8–9 Pt 2, 2001, pp. 929–34, PMID 11787357.
(EN) Fred D. Lublin e Stephen C. Reingold, Defining the clinical course of multiple sclerosis: Results of an international survey, in Neurology, vol. 46, n. 4, aprile 1996, pp. 907–911, DOI:10.1212/WNL.46.4.907, PMID 8780061.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH, Defining the clinical course of multiple sclerosis: the 2013 revisions, in Neurology, vol. 83, n. 3, 2014, pp. 278–86, DOI:10.1212/WNL.0000000000000560, PMC 4117366, PMID 24871874.
Trojano M, Paolicelli D, The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes, in Neurol. Sci., vol. 22, Suppl 2, novembre 2001, pp. S98–102, DOI:10.1007/s100720100044, PMID 11794488. URL consultato il 17 ottobre 2011 (archiviato dall'url originale il 20 ottobre 2014).
Poser CM, Brinar VV, Diagnostic criteria for multiple sclerosis: an historical review, in Clin Neurol Neurosurg, vol. 106, n. 3, giugno 2004, pp. 147–58, DOI:10.1016/j.clineuro.2004.02.004, PMID 15177763.
McDonald WI, Compston A, Edan G, et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, in Ann. Neurol., vol. 50, n. 1, luglio 2001, pp. 121–7, DOI:10.1002/ana.1032, PMID 11456302.
Polman CH, Reingold SC, Edan G, et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria", in Ann. Neurol., vol. 58, n. 6, dicembre 2005, pp. 840–6, DOI:10.1002/ana.20703, PMID 16283615.
Rashid W, Miller DH, Recent advances in neuroimaging of multiple sclerosis, in Semin Neurol, vol. 28, n. 1, febbraio 2008, pp. 46–55, DOI:10.1055/s-2007-1019127, PMID 18256986.
G. Poloni, A. Minagar; EM. Haacke; R. Zivadinov, Recent developments in imaging of multiple sclerosis., in Neurologist, vol. 17, n. 4, luglio 2011, pp. 185-204, DOI:10.1097/NRL.0b013e31821a2643, PMID 21712664.
D. Buck, A. Förschler; C. Lapa; T. Schuster; P. Vollmar; T. Korn; S. Nessler; C. Stadelmann; A. Drzezga; AK. Buck; HJ. Wester, 18F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions., in J Nucl Med, vol. 53, n. 8, agosto 2012, pp. 1269-76, DOI:10.2967/jnumed.111.102608, PMID 22738927.
Link H, Huang YM, Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness, in J. Neuroimmunol., vol. 180, 1–2, novembre 2006, pp. 17–28, DOI:10.1016/j.jneuroim.2006.07.006, PMID 16945427.
Gronseth GS, Ashman EJ, Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Neurology, vol. 54, n. 9, maggio 2000, pp. 1720–5, PMID 10802774.
CH. Polman, SC. Reingold; B. Banwell; M. Clanet; JA. Cohen; M. Filippi; K. Fujihara; E. Havrdova; M. Hutchinson; L. Kappos; FD. Lublin, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria., in Ann Neurol, vol. 69, n. 2, febbraio 2011, pp. 292-302, DOI:10.1002/ana.22366, PMID 21387374.
AJ. Thompson, BL. Banwell; F. Barkhof; WM. Carroll; T. Coetzee; G. Comi; J. Correale; F. Fazekas; M. Filippi; MS. Freedman; K. Fujihara, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria., in Lancet Neurol, vol. 17, n. 2, febbraio 2018, pp. 162-173, DOI:10.1016/S1474-4422(17)30470-2, PMID 29275977.
LA. Rolak, JO. Fleming, The differential diagnosis of multiple sclerosis., in Neurologist, vol. 13, n. 2, marzo 2007, pp. 57-72, DOI:10.1097/01.nrl.0000254705.39956.34, PMID 17351525.
Solomon AJ et al., The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study (PDF), in Neurology, vol. 87, n. 13, settembre 2016, pp. 1393-9, DOI:10.1212/WNL.0000000000003152, PMID 27581217.
Burton JM, O'Connor PW, Hohol M, Beyene J, Oral versus intravenous steroids for treatment of relapses in multiple sclerosis, in Jodie M Burton (a cura di), Cochrane Database Syst Rev, n. 3, 2009, pp. CD006921, DOI:10.1002/14651858.CD006921.pub2, PMID 19588409.
G. Filippini, L. Munari; B. Incorvaia; GC. Ebers; C. Polman; R. D'Amico; GP. Rice, Interferons in relapsing remitting multiple sclerosis: a systematic review., in Lancet, vol. 361, n. 9357, febbraio 2003, pp. 545-52, DOI:10.1016/S0140-6736(03)12512-3, PMID 12598138.
L. Munari, R. Lovati; A. Boiko, Therapy with glatiramer acetate for multiple sclerosis., in Cochrane Database Syst Rev, n. 1, 2004, pp. CD004678, DOI:10.1002/14651858.CD004678, PMID 14974077.
CH. Polman, PW. O'Connor; E. Havrdova; M. Hutchinson; L. Kappos; DH. Miller; JT. Phillips; FD. Lublin; G. Giovannoni; A. Wajgt; M. Toal, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis., in N Engl J Med, vol. 354, n. 9, marzo 2006, pp. 899-910, DOI:10.1056/NEJMoa044397, PMID 16510744.
JA. Cohen, F. Barkhof; G. Comi; HP. Hartung; BO. Khatri; X. Montalban; J. Pelletier; R. Capra; P. Gallo; G. Izquierdo; K. Tiel-Wilck, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis., in N Engl J Med, vol. 362, n. 5, febbraio 2010, pp. 402-15, DOI:10.1056/NEJMoa0907839, PMID 20089954.
L. Kappos, EW. Radue; P. O'Connor; C. Polman; R. Hohlfeld; P. Calabresi; K. Selmaj; C. Agoropoulou; M. Leyk; L. Zhang-Auberson; P. Burtin, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis., in N Engl J Med, vol. 362, n. 5, febbraio 2010, pp. 387-401, DOI:10.1056/NEJMoa0909494, PMID 20089952.
F. Martinelli Boneschi, M. Rovaris; R. Capra; G. Comi, Mitoxantrone for multiple sclerosis., in Cochrane Database Syst Rev, n. 4, 2005, pp. CD002127, DOI:10.1002/14651858.CD002127.pub2, PMID 16235298.
Magne D, Mézin F, Palmer G, Guerne PA, The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha, in Inflamm. Res., vol. 55, n. 11, 2006, pp. 469–75, DOI:10.1007/s00011-006-5196-x, PMID 17122964.
Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study, in Lancet Neurol, vol. 13, n. 7, 2014, pp. 657–65, DOI:10.1016/S1474-4422(14)70068-7, PMID 24794721.
Kita M, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Sarda SP, Agarwal S, Kong J, Zhang A, Viglietta V, Sheikh SI, Seidman E, Dawson KT, Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study, in Mult. Scler., vol. 20, n. 2, 2014, pp. 253–7, DOI:10.1177/1352458513507818, PMID 24150778.
Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S, Zhang A, Sheikh SI, Seidman E, Dawson KT, Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study, in Mult. Scler., vol. 20, n. 2, 2014, pp. 243–52, DOI:10.1177/1352458513507817, PMID 24150779.
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA, Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes, in Lancet Neurol, vol. 10, n. 4, 2011, pp. 338–48, DOI:10.1016/S1474-4422(11)70020-5, PMID 21397567.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial, in Lancet, vol. 380, n. 9856, 2012, pp. 1829–39, DOI:10.1016/S0140-6736(12)61768-1, PMID 23122650.
Comi G, Treatment of multiple sclerosis: role of natalizumab, in Neurol. Sci., 30, Suppl 2, S2, ottobre 2009, pp. S155–8, DOI:10.1007/s10072-009-0147-2, PMID 19882365.
Johnson KP, Control of multiple sclerosis relapses with immunomodulating agents, in J. Neurol. Sci., vol. 256, Suppl 1, 2007, pp. S23–8, DOI:10.1016/j.jns.2007.01.060, PMID 17350652.
Martinelli Boneschi F, Rovaris M, Capra R, Comi G, Mitoxantrone for multiple sclerosis, in Filippo Martinelli Boneschi (a cura di), Cochrane database of systematic reviews (Online), n. 4, 2005, pp. CD002127, DOI:10.1002/14651858.CD002127.pub2, PMID 16235298.
Leary SM, Thompson AJ, Primary progressive multiple sclerosis: current and future treatment options, in CNS Drugs, vol. 19, n. 5, 2005, pp. 369–76, DOI:10.2165/00023210-200519050-00001, PMID 15907149.
Sládková T, Kostolanský F, The role of cytokines in the immune response to influenza A virus infection, in Acta Virol., vol. 50, n. 3, 2006, pp. 151–62, PMID 17131933.
Munari L, Lovati R, Boiko A, Therapy with glatiramer acetate for multiple sclerosis, in Luca M. Munari (a cura di), Cochrane database of systematic reviews (Online), n. 1, 2004, pp. CD004678, DOI:10.1002/14651858.CD004678, PMID 14974077.
Tremlett H, Oger J, Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis, in J. Neurol., vol. 251, n. 11, novembre 2004, pp. 1297–303, DOI:10.1007/s00415-004-0619-5, PMID 15592724.
C. Syburra, S. Passi, Oxidative stress in patients with multiple sclerosis., in Ukr Biokhim Zh, vol. 71, n. 3, pp. 112-5, PMID 10609336.
GH. Marracci, RE. Jones; GP. McKeon; DN. Bourdette, Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis., in J Neuroimmunol, vol. 131, n. 1-2, ottobre 2002, pp. 104-14, PMID 12458042.
Kesselring J, Beer S, Symptomatic therapy and neurorehabilitation in multiple sclerosis, in The Lancet Neurology, vol. 4, n. 10, 2005, pp. 643–52, DOI:10.1016/S1474-4422(05)70193-9, PMID 16168933.
A. Kheder, KP. Nair, Spasticity: pathophysiology, evaluation and management., in Pract Neurol, vol. 12, n. 5, ottobre 2012, pp. 289-98, DOI:10.1136/practneurol-2011-000155, PMID 22976059.
Cath Smith, Leigh Hale; Kärin Olson; Anthony Schneiders, How does exercise influence fatigue in people with multiple sclerosis?, in Disability and Rehabilitation, vol. 31, n. 9, 2009, pp. 685–692, DOI:10.1080/09638280802273473, PMID 18841515.
Stroud NM, Minahan CL, The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosis, in Health and Quality of Life Outcomes, vol. 7, 2009, p. 68, DOI:10.1186/1477-7525-7-68, PMC 2717927, PMID 19619337.
Rietberg MB, Brooks D, Uitdehaag BMJ, Kwakkel G, Exercise therapy for multiple sclerosis, in Gert Kwakkel (a cura di), Cochrane Database of Systematic Reviews, CD003980, n. 1, 2005, pp. CD003980, DOI:10.1002/14651858.CD003980.pub2, PMID 15674920.
Dalgas U, Stenager E, Jakobsen J et al., Resistance training improves muscle strength and functional capacity in multiple sclerosis, in Neurology, vol. 73, n. 18, 2009, pp. 1478–1484, DOI:10.1212/WNL.0b013e3181bf98b4, PMID 19884575.
SL Davis, Wilson, TE, White, AT, Frohman, EM, Thermoregulation in multiple sclerosis., in Journal of applied physiology (Bethesda, Md. : 1985), vol. 109, n. 5, 2010 Nov, pp. 1531–7, DOI:10.1152/japplphysiol.00460.2010, PMC 2980380, PMID 20671034.
Petro DJ, Ellenberger C, Treatment of Human Spasticity with Tetrahydrocannabinol, in Journal of Clinical Pharmacology 1981; 21: 413-416, PMID 6271839. URL consultato il 14 ottobre 2022 (archiviato dall'url originale l'11 aprile 2013).
Clifford D, Tetrahydrocannabinol for Tremors in Multiple Sclerosis, in Annals of Neurology 1983; 13: 669-671, PMID 6309074.
Meinck H et al, Effects of cannabinoids on spasticity and ataxia in multiple sclerosis, in Journal of Neurology 1989; 226: 120-122, PMID 2709054.
Martyn CN et al, Nabilone in the treatment of multiple sclerosis, in Lancet 1995;345:579, PMID 7776785.
Consroe P et al, The perceived effects of smoked cannabis on patients with multiple sclerosis, in European Neurology 1997;38(1):44-48, PMID 9252798.
Kubajewska I, Constantinescu CS, Cannabinoids and experimental models of multiple sclerosis, in Immunobiology 2010; 215(8): 647-57, DOI:10.1016/j.imbio.2009.08.004, PMID 19765854.
de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J, Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects, in Neuropharmacology 2012; 62(7): 2299-308, DOI:10.1016/j.neuropharm.2012.01.030, PMID 22342378.
Buccellato E, Carretta D, Utan A, Cavina C, Speroni E, Grassi G, Candeletti S, Romualdi P, Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis, in J Ethnopharmacol 2011; 133(3): 1033-1038, DOI:10.1016/j.jep.2010.11.035, PMID 21094240.
Berrendero F, Sánchez A, Cabranes A, Puerta C, Ramos JA, García-Merino A, Fernández-Ruiz J, Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis, in Synapse 2001; 41(3): 195-202, PMID 11391780.
John Zajicek et al. on behalf of the UK MS Research Group, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial (PDF), in Lancet 2003 8; 362(9395): 1517-1526, PMID 14615106.
Svendsen KB, Jensen TS, Bach FW, Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial, in British Medical Journal 2004; 329: 253, PMID 15258006.
Wissel J, Haydn T, Muller J, Brenneis C, Berger T, Poewe W, Schelosky LD, Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial, in J Neurol 2006; 253(10): 1337-1341, PMID 16988792.
Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M, Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study, in Multiple Sclerosis 2004; 10(4): 417-24, PMID 15327040 (archiviato dall'url originale il 1º luglio 2012).
Wade DT, Makela P, Robson P, House H, Bateman C, Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients, in Multiple Sclerosis 2004; 10(4): 434-41, PMID 15327042. URL consultato il 23 novembre 2012 (archiviato dall'url originale il 27 gennaio 2013).
Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; on behalf of the MUSEC Research Group, Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial, in J Neurol Neurosurg Psychiatry. 2012 Jul 12., PMID 22791906.
Rog DJ, Nurmikko TJ, Friede T, Young CA, Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis, in Neurology 2005; 65(6): 812-9, PMID 16186518.
Collin C, Davies P, Mutiboko IK, Ratcliffe S, for the Sativex Spasticity in MS Study Group, Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis, in Eur J Neurology 2007; 14(3): 290–296, PMID 17355549.
Centonze D, Mori F, Koch G, Buttari F, Codecà C, Rossi S, Cencioni MT, Bari M, Fiore S, Bernardi G, Battistini L, Maccarrone M, Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis, in Neurol Sci 2009; 30(6): 531-534, PMID 19768368.
Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P; the Sativex Spasticity Study Group, A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis, in Eur J Neurol 2011; 18(9): 1122-31, PMID 21362108.
Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R, A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols), in Mult Scler 2012; 18(2): 219-28, PMID 21878454. URL consultato il 14 ottobre 2022 (archiviato dall'url originale l'11 aprile 2013).
Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B, Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial, in CMAJ 2012; 184(10): 1143-50, PMID 22586334.
Oreja-Guevara C, Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids, in Rev Neurol 2012; 55(7): 421-30, PMID 23011861.
Leussink VI, Husseini L, Warnke C, Broussalis E, Hartung HP, Kieseier BC., Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity, in Ther Adv Neurol Disord 2012; 5(5): 255–266., PMID 22973422.
Grotenhermen F, Müller-Vahl K, The therapeutic potential of cannabis and cannabinoids, in Dtsch Arztebl Int 2012; 109(29-30): 495-501, PMID 23008748.
Truini A, Galeotti F, Cruccu G., Treating pain in multiple sclerosis ^{[collegamento interrotto]}, in Expert Opin Pharmacother 2011; 12(15): 2355-68., PMID 21916786.
Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P., A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis., 2010, PMID 20427749.
Hayes CE., Vitamin D: a natural inhibitor of multiple sclerosis., 2000, PMID 11115787.
Charles Pierrot-Deseilligny, Clinical implications of a possible role of vitamin D in multiple sclerosis, 2009, PMID 20427749.
BA. Cree, 2014 multiple sclerosis therapeutic update., in Neurohospitalist, vol. 4, n. 2, aprile 2014, pp. 63-5, DOI:10.1177/1941874414525410, PMID 24707333.
Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D., Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis., 2012, PMID 22926855.
Olsen SA, A review of complementary and alternative medicine (CAM) by people with multiple sclerosis, in Occup Ther Int, vol. 16, n. 1, 2009, pp. 57–70, DOI:10.1002/oti.266, PMID 19222053.
Farinotti M, Simi S, Di Pietrantonj C, et al., Dietary interventions for multiple sclerosis, in Mariangela Farinotti (a cura di), Cochrane database of systematic reviews (Online), n. 1, 2007, pp. CD004192, DOI:10.1002/14651858.CD004192.pub2, PMID 17253500.
A. Kostianovsky, P. Maskin; MM. Noriega; C. Soler; I. Bonelli; CS. Riley; KC. O'Connor; CN. Saubidet; PA. Alvarez, Acute demyelinating disease after oral therapy with herbal extracts., in Case Rep Neurol, vol. 3, n. 2, maggio 2011, pp. 141-6, PMID 21738505.
Bennett M, Heard R, Hyperbaric oxygen therapy for multiple sclerosis, in Michael H Bennett (a cura di), Cochrane database of systematic reviews (Online), n. 1, 2004, pp. CD003057, DOI:10.1002/14651858.CD003057.pub2, PMID 14974004.
Phadke JG, Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland, in J. Neurol. Neurosurg. Psychiatr., vol. 50, n. 5, maggio 1987, pp. 523–31, DOI:10.1136/jnnp.50.5.523, PMC 1031962, PMID 3495637.
Myhr KM, Riise T, Vedeler C, et al, Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension, in Mult. Scler., vol. 7, n. 1, febbraio 2001, pp. 59–65, PMID 11321195. URL consultato il 20 settembre 2012 (archiviato dall'url originale il 21 febbraio 2021).
LI. Iezzoni, M. Ogg, Hard lessons from a long hospital stay., in Am J Nurs, vol. 112, n. 4, aprile 2012, pp. 39-42, DOI:10.1097/01.NAJ.0000413457.53110.3a, PMID 22456565.
Cohen JA, Emerging therapies for relapsing multiple sclerosis, in Arch. Neurol., vol. 66, n. 7, luglio 2009, pp. 821–8, DOI:10.1001/archneurol.2009.104, PMID 19597083.
Kieseier BC, Calabresi PA, PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis, in CNS Drugs, vol. 26, n. 3, 2012, pp. 205–14, PMID 22201341 (archiviato dall'url originale il 21 giugno 2012).
Kappos L, EW Radue, P O'Connor, C Polman, R Hohlfeld, P Calabresi, K Selmaj, C Agoropoulou e M Leyk, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, in N Eng J Med, vol. 362, n. 5, febbraio 2010, pp. 387–401, DOI:10.1056/NEJMoa0909494, PMID 20089952.
Cohen JA, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, J Pelletier, R Capra e P Gallo, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, in N Eng J Med, vol. 362, n. 5, febbraio 2010, pp. 402–415, DOI:10.1056/NEJMoa0907839, PMID 20089954.
M. Gironi, F. Martinelli-Boneschi; P. Sacerdote; C. Solaro; M. Zaffaroni; R. Cavarretta; L. Moiola; S. Bucello; M. Radaelli; V. Pilato; M. Rodegher, A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis., in Mult Scler, vol. 14, n. 8, settembre 2008, pp. 1076-83, DOI:10.1177/1352458508095828, PMID 18728058.
Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G, A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis, in Multiple Sclerosis, vol. 14, n. 8, 2008, pp. 1076–83, DOI:10.1177/1352458508095828, PMID 18728058.
YP. Agrawal, Low dose naltrexone therapy in multiple sclerosis., in Med Hypotheses, vol. 64, n. 4, 2005, pp. 721-4, DOI:10.1016/j.mehy.2004.09.024, PMID 15694688.
Harris VK, Sadiq SA, Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making, in Mol Diagn Ther, vol. 13, n. 4, 2009, pp. 225–44, DOI:10.2165/11313470-000000000-00000, PMID 19712003.
Zamboni P, Galeotti R, Menegatti E, et al., Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis, in J. Neurol. Neurosurg. Psychiatr., vol. 80, n. 4, aprile 2009, pp. 392–9, DOI:10.1136/jnnp.2008.157164, PMC 2647682, PMID 19060024.
Qiu J, Venous abnormalities and multiple sclerosis: another breakthrough claim?, in Lancet Neurol, vol. 9, n. 5, maggio 2010, pp. 464–5, DOI:10.1016/S1474-4422(10)70098-3, PMID 20398855.
Ghezzi A, Comi G, Federico A, Chronic cerebro-spinal venous insufficiency (CCSVI) and multiple sclerosis, in Neurol. Sci., vol. 32, n. 1, febbraio 2011, pp. 17–21, DOI:10.1007/s10072-010-0458-3, PMID 21161309.
Dorne H, Zaidat OO, Fiorella D, Hirsch J, Prestigiacomo C, Albuquerque F, Tarr RW., Chronic cerebrospinal venous insufficiency and the doubtful promise of an endovascular treatment for multiple sclerosis, in J NeuroIntervent Surg, vol. 2, n. 4, ottobre 2010, pp. 309–311, DOI:10.1136/jnis.2010.003947, PMID 21990639.
Khan O, Filippi M, Freedman MS, Barkhof F, Dore-Duffy P, Lassmann H, Trapp B, Bar-Or A, Zak I, Siegel MJ, Lisak R, Chronic cerebrospinal venous insufficiency and multiple sclerosis, in Annals of neurology, vol. 67, n. 3, Annals of Neurology, 12 febbraio 2010, pp. 286–90, DOI:10.1002/ana.22001, PMID 20373339.

nlm.nih.gov

(EN) Interferon beta-1a Subcutaneous Injection, su nlm.nih.gov, Medline Plus. URL consultato il 1º ottobre 2012.
(EN) Glatiramer Injection, su nlm.nih.gov, Medline Plus. URL consultato il 1º ottobre 2012.
(EN) Natalizumab Injection, su nlm.nih.gov, Medline Plus. URL consultato il 1º ottobre 2012.
(EN) Mitoxantrone Injection, su nlm.nih.gov, Medline Plus. URL consultato il 1º ottobre 2012.
(EN) US National Library of Medicine (Medline), Riluzole, su nlm.nih.gov. URL consultato il 27 ottobre 2012.
(EN) US National Library of Medicine (Medline), Azathioprine, su nlm.nih.gov. URL consultato il 27 ottobre 2012.
(EN) US National Library of Medicine (Medline), Methotrexate, su nlm.nih.gov. URL consultato il 27 ottobre 2012.
(EN) US National Library of Medicine (Medline), Cladribine, su nlm.nih.gov. URL consultato il 27 ottobre 2012.
US National Library of Medicine (Medline), Cyclophosphamide, su nlm.nih.gov. URL consultato il 27 ottobre 2012.

oadoi.org

Compston A, Coles A, Multiple sclerosis, in Lancet, vol. 372, n. 9648, ottobre 2008, pp. 1502–17, DOI:10.1016/S0140-6736(08)61620-7, PMID 18970977.
Compston A, Coles A, Multiple sclerosis, in Lancet, vol. 359, n. 9313, aprile 2002, pp. 1221–31, DOI:10.1016/S0140-6736(02)08220-X, PMID 11955556.
Weinshenker BG, Natural history of multiple sclerosis, in Ann. Neurol., vol. 36, Suppl, 1994, pp. S6–11, DOI:10.1002/ana.410360704, PMID 8017890.
Lassmann H, Multiple sclerosis pathology: evolution of pathogenetic concepts, in Brain Pathology, vol. 15, n. 3, luglio 2005, pp. 217–22, DOI:10.1111/j.1750-3639.2005.tb00523.x, PMID 16196388.
T. Holmøy, A Norse contribution to the history of neurological diseases., in Eur Neurol, vol. 55, n. 1, 2006, pp. 57-8, DOI:10.1159/000091431, PMID 16479124.
Medaer R, Does the history of multiple sclerosis go back as far as the 14th century?, in Acta Neurol. Scand., vol. 60, n. 3, settembre 1979, pp. 189–92, DOI:10.1111/j.1600-0447.1979.tb08970.x, PMID 390966.
Pearce JM, Historical descriptions of multiple sclerosis, in Eur. Neurol., vol. 54, n. 1, 2005, pp. 49–53, DOI:10.1159/000087387, PMID 16103678.
Marrie RA, Environmental risk factors in multiple sclerosis aetiology, in Lancet Neurol, vol. 3, n. 12, dicembre 2004, pp. 709–18, DOI:10.1016/S1474-4422(04)00933-0, PMID 15556803.
Miller DH, Leary SM, Primary-progressive multiple sclerosis, in Lancet Neurol, vol. 6, n. 10, ottobre 2007, pp. 903–12, DOI:10.1016/S1474-4422(07)70243-0, PMID 17884680.
Alwan S, Sadovnick AD, Multiple sclerosis and pregnancy: maternal considerations, in Womens Health (Lond Engl), vol. 8, n. 4, luglio 2012, pp. 399–414, DOI:10.2217/whe.12.33, PMID 22757731.
Alonso A, Hernán MA, Temporal trends in the incidence of multiple sclerosis: a systematic review, in Neurology, vol. 71, n. 2, luglio 2008, pp. 129–35, DOI:10.1212/01.wnl.0000316802.35974.34, PMID 18606967.
M Pugliatti, Sotgiu, S, Rosati, G, The worldwide prevalence of multiple sclerosis, in Clinical neurology and neurosurgery, vol. 104, n. 3, 2002 Jul, pp. 182–91, DOI:10.1016/S0303-8467(02)00036-7, PMID 12127652.
Dyment DA, Ebers GC, Sadovnick AD, Genetics of multiple sclerosis, in Lancet Neurol, vol. 3, n. 92, febbraio 2004, pp. 104–10, DOI:10.1016/S1474-4422(03)00663-X, PMID 14747002.
Ascherio A, Munger KL, Simon KC, Vitamin D and multiple sclerosis, in Lancet Neurol, vol. 9, n. 6, giugno 2010, pp. 599–612, DOI:10.1016/S1474-4422(10)70086-7, PMID 20494325.
Kulie T, Groff A, Redmer J, Hounshell J, Schrager S, Vitamin D: an evidence-based review, in J Am Board Fam Med, vol. 22, n. 6, 2009, pp. 698–706, DOI:10.3122/jabfm.2009.06.090037, PMID 19897699.
Spitsin S, Koprowski H, Role of uric acid in multiple sclerosis, in Curr. Top. Microbiol. Immunol., Current Topics in Microbiology and Immunology, vol. 318, 2008, pp. 325–42, DOI:10.1007/978-3-540-73677-6_13, ISBN 978-3-540-73676-9, PMID 18219824.
Gilden DH, Infectious causes of multiple sclerosis, in The Lancet Neurology, vol. 4, n. 3, marzo 2005, pp. 195–202, DOI:10.1016/S1474-4422(05)01017-3, PMID 15721830.
Pittock SJ, Lucchinetti CF, The pathology of MS: new insights and potential clinical applications, in Neurologist, vol. 13, n. 2, marzo 2007, pp. 45–56, DOI:10.1097/01.nrl.0000253065.31662.37, PMID 17351524.
ET. Wood, I. Ronen; A. Techawiboonwong; CK. Jones; PB. Barker; P. Calabresi; D. Harrison; DS. Reich, Investigating axonal damage in multiple sclerosis by diffusion tensor spectroscopy., in J Neurosci, vol. 32, n. 19, maggio 2012, pp. 6665-9, DOI:10.1523/JNEUROSCI.0044-12.2012, PMID 22573688.
Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C, T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis, in Glia, vol. 36, n. 2, novembre 2001, pp. 220–34, DOI:10.1002/glia.1111, PMID 11596130.
H. Nakajima, T. Hosokawa; M. Sugino; F. Kimura; J. Sugasawa; T. Hanafusa; T. Takahashi, Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis., in BMC Neurol, vol. 10, 2010, p. 45, DOI:10.1186/1471-2377-10-45, PMID 20565857.
Tataru N, Vidal C, Decavel P, Berger E, Rumbach L, Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis, in Neuroepidemiology, vol. 27, n. 1, 2006, pp. 28–32, DOI:10.1159/000094233, PMID 16804331.
Heesen C, Mohr DC, Huitinga I, et al., Stress regulation in multiple sclerosis: current issues and concepts, in Mult. Scler., vol. 13, n. 2, marzo 2007, pp. 143–8, DOI:10.1177/1352458506070772, PMID 17439878.
J. Correale, MC. Ysrraelit; MP. Fiol, Benign Multiple Sclerosis: Does it exist?, in Curr Neurol Neurosci Rep, vol. 12, n. 5, ottobre 2012, pp. 601-9, DOI:10.1007/s11910-012-0292-5, PMID 22777531.
K. Hawker, Primary progressive multiple sclerosis., in Continuum (Minneap Minn), vol. 16, 5 Multiple Sclerosis, ottobre 2010, pp. 211-25, DOI:10.1212/01.CON.0000389943.81981.3b, PMID 22810607.
(EN) Fred D. Lublin e Stephen C. Reingold, Defining the clinical course of multiple sclerosis: Results of an international survey, in Neurology, vol. 46, n. 4, aprile 1996, pp. 907–911, DOI:10.1212/WNL.46.4.907, PMID 8780061.
Poser CM, Brinar VV, Diagnostic criteria for multiple sclerosis: an historical review, in Clin Neurol Neurosurg, vol. 106, n. 3, giugno 2004, pp. 147–58, DOI:10.1016/j.clineuro.2004.02.004, PMID 15177763.
Rashid W, Miller DH, Recent advances in neuroimaging of multiple sclerosis, in Semin Neurol, vol. 28, n. 1, febbraio 2008, pp. 46–55, DOI:10.1055/s-2007-1019127, PMID 18256986.
G. Poloni, A. Minagar; EM. Haacke; R. Zivadinov, Recent developments in imaging of multiple sclerosis., in Neurologist, vol. 17, n. 4, luglio 2011, pp. 185-204, DOI:10.1097/NRL.0b013e31821a2643, PMID 21712664.
Link H, Huang YM, Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness, in J. Neuroimmunol., vol. 180, 1–2, novembre 2006, pp. 17–28, DOI:10.1016/j.jneuroim.2006.07.006, PMID 16945427.
AJ. Thompson, BL. Banwell; F. Barkhof; WM. Carroll; T. Coetzee; G. Comi; J. Correale; F. Fazekas; M. Filippi; MS. Freedman; K. Fujihara, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria., in Lancet Neurol, vol. 17, n. 2, febbraio 2018, pp. 162-173, DOI:10.1016/S1474-4422(17)30470-2, PMID 29275977.
LA. Rolak, JO. Fleming, The differential diagnosis of multiple sclerosis., in Neurologist, vol. 13, n. 2, marzo 2007, pp. 57-72, DOI:10.1097/01.nrl.0000254705.39956.34, PMID 17351525.
Burton JM, O'Connor PW, Hohol M, Beyene J, Oral versus intravenous steroids for treatment of relapses in multiple sclerosis, in Jodie M Burton (a cura di), Cochrane Database Syst Rev, n. 3, 2009, pp. CD006921, DOI:10.1002/14651858.CD006921.pub2, PMID 19588409.
G. Filippini, L. Munari; B. Incorvaia; GC. Ebers; C. Polman; R. D'Amico; GP. Rice, Interferons in relapsing remitting multiple sclerosis: a systematic review., in Lancet, vol. 361, n. 9357, febbraio 2003, pp. 545-52, DOI:10.1016/S0140-6736(03)12512-3, PMID 12598138.
L. Munari, R. Lovati; A. Boiko, Therapy with glatiramer acetate for multiple sclerosis., in Cochrane Database Syst Rev, n. 1, 2004, pp. CD004678, DOI:10.1002/14651858.CD004678, PMID 14974077.
CH. Polman, PW. O'Connor; E. Havrdova; M. Hutchinson; L. Kappos; DH. Miller; JT. Phillips; FD. Lublin; G. Giovannoni; A. Wajgt; M. Toal, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis., in N Engl J Med, vol. 354, n. 9, marzo 2006, pp. 899-910, DOI:10.1056/NEJMoa044397, PMID 16510744.
JA. Cohen, F. Barkhof; G. Comi; HP. Hartung; BO. Khatri; X. Montalban; J. Pelletier; R. Capra; P. Gallo; G. Izquierdo; K. Tiel-Wilck, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis., in N Engl J Med, vol. 362, n. 5, febbraio 2010, pp. 402-15, DOI:10.1056/NEJMoa0907839, PMID 20089954.
L. Kappos, EW. Radue; P. O'Connor; C. Polman; R. Hohlfeld; P. Calabresi; K. Selmaj; C. Agoropoulou; M. Leyk; L. Zhang-Auberson; P. Burtin, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis., in N Engl J Med, vol. 362, n. 5, febbraio 2010, pp. 387-401, DOI:10.1056/NEJMoa0909494, PMID 20089952.
F. Martinelli Boneschi, M. Rovaris; R. Capra; G. Comi, Mitoxantrone for multiple sclerosis., in Cochrane Database Syst Rev, n. 4, 2005, pp. CD002127, DOI:10.1002/14651858.CD002127.pub2, PMID 16235298.
Magne D, Mézin F, Palmer G, Guerne PA, The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha, in Inflamm. Res., vol. 55, n. 11, 2006, pp. 469–75, DOI:10.1007/s00011-006-5196-x, PMID 17122964.
Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study, in Lancet Neurol, vol. 13, n. 7, 2014, pp. 657–65, DOI:10.1016/S1474-4422(14)70068-7, PMID 24794721.
Kita M, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Sarda SP, Agarwal S, Kong J, Zhang A, Viglietta V, Sheikh SI, Seidman E, Dawson KT, Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study, in Mult. Scler., vol. 20, n. 2, 2014, pp. 253–7, DOI:10.1177/1352458513507818, PMID 24150778.
Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S, Zhang A, Sheikh SI, Seidman E, Dawson KT, Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study, in Mult. Scler., vol. 20, n. 2, 2014, pp. 243–52, DOI:10.1177/1352458513507817, PMID 24150779.
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA, Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes, in Lancet Neurol, vol. 10, n. 4, 2011, pp. 338–48, DOI:10.1016/S1474-4422(11)70020-5, PMID 21397567.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial, in Lancet, vol. 380, n. 9856, 2012, pp. 1829–39, DOI:10.1016/S0140-6736(12)61768-1, PMID 23122650.
Comi G, Treatment of multiple sclerosis: role of natalizumab, in Neurol. Sci., 30, Suppl 2, S2, ottobre 2009, pp. S155–8, DOI:10.1007/s10072-009-0147-2, PMID 19882365.
Johnson KP, Control of multiple sclerosis relapses with immunomodulating agents, in J. Neurol. Sci., vol. 256, Suppl 1, 2007, pp. S23–8, DOI:10.1016/j.jns.2007.01.060, PMID 17350652.
Martinelli Boneschi F, Rovaris M, Capra R, Comi G, Mitoxantrone for multiple sclerosis, in Filippo Martinelli Boneschi (a cura di), Cochrane database of systematic reviews (Online), n. 4, 2005, pp. CD002127, DOI:10.1002/14651858.CD002127.pub2, PMID 16235298.
Leary SM, Thompson AJ, Primary progressive multiple sclerosis: current and future treatment options, in CNS Drugs, vol. 19, n. 5, 2005, pp. 369–76, DOI:10.2165/00023210-200519050-00001, PMID 15907149.
Munari L, Lovati R, Boiko A, Therapy with glatiramer acetate for multiple sclerosis, in Luca M. Munari (a cura di), Cochrane database of systematic reviews (Online), n. 1, 2004, pp. CD004678, DOI:10.1002/14651858.CD004678, PMID 14974077.
Tremlett H, Oger J, Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis, in J. Neurol., vol. 251, n. 11, novembre 2004, pp. 1297–303, DOI:10.1007/s00415-004-0619-5, PMID 15592724.
Kesselring J, Beer S, Symptomatic therapy and neurorehabilitation in multiple sclerosis, in The Lancet Neurology, vol. 4, n. 10, 2005, pp. 643–52, DOI:10.1016/S1474-4422(05)70193-9, PMID 16168933.
A. Kheder, KP. Nair, Spasticity: pathophysiology, evaluation and management., in Pract Neurol, vol. 12, n. 5, ottobre 2012, pp. 289-98, DOI:10.1136/practneurol-2011-000155, PMID 22976059.
Rietberg MB, Brooks D, Uitdehaag BMJ, Kwakkel G, Exercise therapy for multiple sclerosis, in Gert Kwakkel (a cura di), Cochrane Database of Systematic Reviews, CD003980, n. 1, 2005, pp. CD003980, DOI:10.1002/14651858.CD003980.pub2, PMID 15674920.
Dalgas U, Stenager E, Jakobsen J et al., Resistance training improves muscle strength and functional capacity in multiple sclerosis, in Neurology, vol. 73, n. 18, 2009, pp. 1478–1484, DOI:10.1212/WNL.0b013e3181bf98b4, PMID 19884575.
Kubajewska I, Constantinescu CS, Cannabinoids and experimental models of multiple sclerosis, in Immunobiology 2010; 215(8): 647-57, DOI:10.1016/j.imbio.2009.08.004, PMID 19765854.
de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J, Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects, in Neuropharmacology 2012; 62(7): 2299-308, DOI:10.1016/j.neuropharm.2012.01.030, PMID 22342378.
Buccellato E, Carretta D, Utan A, Cavina C, Speroni E, Grassi G, Candeletti S, Romualdi P, Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis, in J Ethnopharmacol 2011; 133(3): 1033-1038, DOI:10.1016/j.jep.2010.11.035, PMID 21094240.
BA. Cree, 2014 multiple sclerosis therapeutic update., in Neurohospitalist, vol. 4, n. 2, aprile 2014, pp. 63-5, DOI:10.1177/1941874414525410, PMID 24707333.
Olsen SA, A review of complementary and alternative medicine (CAM) by people with multiple sclerosis, in Occup Ther Int, vol. 16, n. 1, 2009, pp. 57–70, DOI:10.1002/oti.266, PMID 19222053.
Farinotti M, Simi S, Di Pietrantonj C, et al., Dietary interventions for multiple sclerosis, in Mariangela Farinotti (a cura di), Cochrane database of systematic reviews (Online), n. 1, 2007, pp. CD004192, DOI:10.1002/14651858.CD004192.pub2, PMID 17253500.
Bennett M, Heard R, Hyperbaric oxygen therapy for multiple sclerosis, in Michael H Bennett (a cura di), Cochrane database of systematic reviews (Online), n. 1, 2004, pp. CD003057, DOI:10.1002/14651858.CD003057.pub2, PMID 14974004.
Cohen JA, Emerging therapies for relapsing multiple sclerosis, in Arch. Neurol., vol. 66, n. 7, luglio 2009, pp. 821–8, DOI:10.1001/archneurol.2009.104, PMID 19597083.
Kappos L, EW Radue, P O'Connor, C Polman, R Hohlfeld, P Calabresi, K Selmaj, C Agoropoulou e M Leyk, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, in N Eng J Med, vol. 362, n. 5, febbraio 2010, pp. 387–401, DOI:10.1056/NEJMoa0909494, PMID 20089952.
Cohen JA, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, J Pelletier, R Capra e P Gallo, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, in N Eng J Med, vol. 362, n. 5, febbraio 2010, pp. 402–415, DOI:10.1056/NEJMoa0907839, PMID 20089954.
M. Gironi, F. Martinelli-Boneschi; P. Sacerdote; C. Solaro; M. Zaffaroni; R. Cavarretta; L. Moiola; S. Bucello; M. Radaelli; V. Pilato; M. Rodegher, A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis., in Mult Scler, vol. 14, n. 8, settembre 2008, pp. 1076-83, DOI:10.1177/1352458508095828, PMID 18728058.
Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G, A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis, in Multiple Sclerosis, vol. 14, n. 8, 2008, pp. 1076–83, DOI:10.1177/1352458508095828, PMID 18728058.
YP. Agrawal, Low dose naltrexone therapy in multiple sclerosis., in Med Hypotheses, vol. 64, n. 4, 2005, pp. 721-4, DOI:10.1016/j.mehy.2004.09.024, PMID 15694688.
Harris VK, Sadiq SA, Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making, in Mol Diagn Ther, vol. 13, n. 4, 2009, pp. 225–44, DOI:10.2165/11313470-000000000-00000, PMID 19712003.
Qiu J, Venous abnormalities and multiple sclerosis: another breakthrough claim?, in Lancet Neurol, vol. 9, n. 5, maggio 2010, pp. 464–5, DOI:10.1016/S1474-4422(10)70098-3, PMID 20398855.
Ghezzi A, Comi G, Federico A, Chronic cerebro-spinal venous insufficiency (CCSVI) and multiple sclerosis, in Neurol. Sci., vol. 32, n. 1, febbraio 2011, pp. 17–21, DOI:10.1007/s10072-010-0458-3, PMID 21161309.
Dorne H, Zaidat OO, Fiorella D, Hirsch J, Prestigiacomo C, Albuquerque F, Tarr RW., Chronic cerebrospinal venous insufficiency and the doubtful promise of an endovascular treatment for multiple sclerosis, in J NeuroIntervent Surg, vol. 2, n. 4, ottobre 2010, pp. 309–311, DOI:10.1136/jnis.2010.003947, PMID 21990639.
Khan O, Filippi M, Freedman MS, Barkhof F, Dore-Duffy P, Lassmann H, Trapp B, Bar-Or A, Zak I, Siegel MJ, Lisak R, Chronic cerebrospinal venous insufficiency and multiple sclerosis, in Annals of neurology, vol. 67, n. 3, Annals of Neurology, 12 febbraio 2010, pp. 286–90, DOI:10.1002/ana.22001, PMID 20373339.
(EN) Claudio Baracchini et al., No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset, in Annals of Neurology, vol. 69, n. 1, DOI:10.1002/ana.22228.

revneurol.com

Oreja-Guevara C, Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids, in Rev Neurol 2012; 55(7): 421-30, PMID 23011861.

springer.com

link.springer.com

Meinck H et al, Effects of cannabinoids on spasticity and ataxia in multiple sclerosis, in Journal of Neurology 1989; 226: 120-122, PMID 2709054.
Wissel J, Haydn T, Muller J, Brenneis C, Berger T, Poewe W, Schelosky LD, Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial, in J Neurol 2006; 253(10): 1337-1341, PMID 16988792.

treccani.it

Dizionario di medicina - Oftalmoplegia internucleare, su treccani.it. URL consultato il 30 settembre 2012.

ucl.ac.uk

discovery.ucl.ac.uk

A. Petzold, Fraser, C.L., Abegg, M., et al., Diagnosis and classification of optic neuritis, in The Lancet Neurology, vol. 21, n. 12, dec 2022, pp. 1120–1134, DOI:10.1016/S1474-4422(22)00200-9, PMID 36179757.

unibo.it

acnpsearch.unibo.it

Compston A, The 150th anniversary of the first depiction of the lesions of multiple sclerosis, in J. Neurol. Neurosurg. Psychiatr., vol. 51, n. 10, ottobre 1988, pp. 1249–52, DOI:10.1136/jnnp.51.10.1249, ISSN 0022-3050 (WC · ACNP), PMC 1032909, PMID 3066846.

web.archive.org

Clanet M, Jean-Martin Charcot. 1825 to 1893 (PDF), in Int MS J, vol. 15, n. 2, giugno 2008, pp. 59–61, PMID 18782501. URL consultato il 14 settembre 2012 (archiviato dall'url originale il 30 marzo 2019).
* Charcot, J., Histologie de la sclerose en plaques, in Gazette des hopitaux, Paris, vol. 41, 1868, pp. 554–5.
(EN) Atlas of MS database, su msif.org, Multiple sclerosis international federation. URL consultato il 12 novembre 2012 (archiviato dall'url originale il 15 ottobre 2012).
Scoperto nuovo gene coinvolto nella sclerosi multipla, su cnr.it, Consiglio Nazionale delle Ricerche. URL consultato il 30 settembre 2012 (archiviato dall'url originale il 14 novembre 2012).
Minagar A, Jy W, Jimenez JJ, Alexander JS., Multiple sclerosis as a vascular disease (PDF), in Neurol Res., vol. 28, n. 3, aprile 2006, pp. 230–5, DOI:10.1179/016164106X98080, PMID 16687046 (archiviato dall'url originale il 16 agosto 2011).
Fattori scatenanti, su sclerosi.org. URL consultato il 20 settembre 2012 (archiviato dall'url originale il 15 ottobre 2012).
Manuale Merck - Malattie demielinizzanti, la sclerosi multipla, su msd-italia.it. URL consultato il 21 settembre 2012 (archiviato dall'url originale l'8 ottobre 2012).
Sintomi e segni della sclerosi multipla, su sclerosi.org. URL consultato il 20 settembre 2012 (archiviato dall'url originale il 27 settembre 2012).
L'incoordinazione dei movimenti, su sclerosi.org. URL consultato il 20 settembre 2012 (archiviato dall'url originale il 15 ottobre 2012).
Neurite ottica retrobulbare, su sclerosi.org. URL consultato il 20 settembre 2012 (archiviato dall'url originale il 5 ottobre 2012).
Disfunzioni intestinali, su sclerosi.org. URL consultato il 20 settembre 2012 (archiviato dall'url originale il 3 ottobre 2012).
Martinelli V, Trauma, stress and multiple sclerosis, in Neurol. Sci., vol. 21, 4 Suppl 2, 2000, pp. S849–52, DOI:10.1007/s100720070024, PMID 11205361. URL consultato il 20 settembre 2012 (archiviato dall'url originale il 1º novembre 2013).
Il decorso clinico della sclerosi multipla, su sclerosi.org. URL consultato il 25 settembre 2012 (archiviato dall'url originale il 17 settembre 2012).
(EN) Multiple Sclerosis Symptom Facts, su themcfox.com. URL consultato il 25 settembre 2012 (archiviato dall'url originale il 16 settembre 2012).
(EN) What We Know About Secondary-Progressive MS (SPMS), su nationalmssociety.org. URL consultato il 25 settembre 2012 (archiviato dall'url originale il 5 ottobre 2012).
Trojano M, Paolicelli D, The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes, in Neurol. Sci., vol. 22, Suppl 2, novembre 2001, pp. S98–102, DOI:10.1007/s100720100044, PMID 11794488. URL consultato il 17 ottobre 2011 (archiviato dall'url originale il 20 ottobre 2014).
Risonanza magnetica nucleare, su sclerosi.org. URL consultato il 5 ottobre 2012 (archiviato dall'url originale il 15 ottobre 2012).
I trattamenti oggi impiegati nella sclerosi multipla, su sclerosi.org. URL consultato il 20 settembre 2012 (archiviato dall'url originale il 15 ottobre 2012).
(EN) Popularity Of Unconventional Medicine, su msif.org, Multiple sclerosis - International federation. URL consultato il 21 settembre 2012 (archiviato dall'url originale il 26 giugno 2010).
The Royal College of Physicians, Multiple Sclerosis. National clinical guideline for diagnosis and management in primary and secondary care (PDF), Salisbury, Wiltshire, Sarum ColourView Group, 2004, pp. 54–57, ISBN 1-86016-182-0. URL consultato il 21 settembre 2012 (archiviato dall'url originale il 4 ottobre 2007). Retrieved on 2010-01-07.
European Medicines Agency, su ema.europa.eu. URL consultato il 1º giugno 2017 (archiviato dall'url originale il 26 maggio 2012).
(EN) NINDS Multiple Sclerosis Information Page, su ninds.nih.gov, National Institute of Neurological Disorders and Stroke. URL consultato il 1º ottobre 2012 (archiviato dall'url originale il 13 febbraio 2016).
18/07/2014 autorizzazione European Medicine Agency, su ema.europa.eu. URL consultato il 1º giugno 2017 (archiviato dall'url originale il 16 marzo 2017).
Antiossidanti, su sclerosi.org. URL consultato il 21 settembre 2012 (archiviato dall'url originale il 28 settembre 2012).
Multiple sclerosis: its effects on you and those you love (PDF), su mssociety.ca, Multiple Sclerosis Society of Canada, 2008. URL consultato l'11 maggio 2011 (archiviato dall'url originale il 17 settembre 2011).
Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M, Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study, in Multiple Sclerosis 2004; 10(4): 417-24, PMID 15327040 (archiviato dall'url originale il 1º luglio 2012).
Wade DT, Makela P, Robson P, House H, Bateman C, Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients, in Multiple Sclerosis 2004; 10(4): 434-41, PMID 15327042. URL consultato il 23 novembre 2012 (archiviato dall'url originale il 27 gennaio 2013).
GW receives Qualifying Notice for approval in Canada for Sativex (Press Release), su gwpharm.com, 21 dicembre 2005 (archiviato dall'url originale il 6 gennaio 2011).
Sativex Mutual Recognition Procedure Closes with Recommendation for Approval in Ten European Countries (Press Release), su gwpharm.com, 8 maggio 2012 (archiviato dall'url originale il 5 ottobre 2012).
Modalità di importazione di specialità medicinali registrate all'estero (PDF), su iss.it, Decreto Ministeriale, 11 febbraio 1997. URL consultato il 24 novembre 2012 (archiviato dall'url originale il 15 agosto 2014).
Myhr KM, Riise T, Vedeler C, et al, Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension, in Mult. Scler., vol. 7, n. 1, febbraio 2001, pp. 59–65, PMID 11321195. URL consultato il 20 settembre 2012 (archiviato dall'url originale il 21 febbraio 2021).
Disturbi vescicali, su sclerosi.org. URL consultato il 30 settembre 2012 (archiviato dall'url originale il 15 ottobre 2012).
Naltrexone a basso dosaggio nella terapia della sclerosi multipla, su xagena.it. URL consultato il 25 settembre 2012 (archiviato dall'url originale il 28 luglio 2013).
ufficiostampa, Pubblicati sulla prestigiosa rivista scientifica americana JAMA Neurology I RISULTATI DELLO STUDIO “EFFICACIA E SICUREZZA NELLA ANGIOPLASTICA VENOSA NELLA SCLEROSI MULTIPLA”, ACRONIMO BRAVE DREAMS-BRAIN VENOUS DRAINAGE EXPLOITED AGAINST MULTIPLE SCLEROSIS, in Azienda Ospedaliero-Universitaria di Ferrara, 18 novembre 2017. URL consultato l'8 marzo 2018 (archiviato dall'url originale il 9 marzo 2018).

webmd.com

Daniel J. DeNoon, FDA Panel Votes to Approve Gilenia, First Oral MS Drug, in WebMD, 2010. URL consultato il 13 giugno 2010.

who.int

(EN) Death and DALY estimates for 2004 by cause for WHO Member States (Persons, all ages) (XLS), su who.int. URL consultato il 28 settembre 2012.

wikiwix.com

archive.wikiwix.com

Kieseier BC, Calabresi PA, PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis, in CNS Drugs, vol. 26, n. 3, 2012, pp. 205–14, PMID 22201341 (archiviato dall'url originale il 21 giugno 2012).

wiley.com

www3.interscience.wiley.com

McDonald WI, Compston A, Edan G et als. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, 2001;50:121-127
Polman CH, Reingold SC, Edan G et als. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”, Ann Neurol, 2005;58:840-846

worldcat.org

Compston A, The 150th anniversary of the first depiction of the lesions of multiple sclerosis, in J. Neurol. Neurosurg. Psychiatr., vol. 51, n. 10, ottobre 1988, pp. 1249–52, DOI:10.1136/jnnp.51.10.1249, ISSN 0022-3050 (WC · ACNP), PMC 1032909, PMID 3066846.